• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Novu Launches mHealth COPD Clinical Trial, Partners with Mayo Clinic, MHS

by Jasmine Pennic 09/15/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Consumer Health Engagement Platform Novu

Novu, a consumer health engagement platform today announced it has been tapped by Minnesota HealthSolutions Corporation (MHS) to partner on a mobile health COPD clinical trial program designed to motivate and monitor people with chronic obstructive pulmonary disease (COPD). Many of the millions of people affected by COPD are not able to participate in pulmonary rehabilitation (PR) in a clinical setting, and the program, delivered through the Novu platform, will enable them to complete home exercise more easily. The program will be evaluated in a controlled human study at the Mayo Clinic.

According to research from the Centers for Disease Control and Prevention (CDC), chronic lower respiratory diseases, including COPD, are the third-leading cause of death in the United States. In 2010, COPD claimed the lives of 134,676 people and the total national medical costs attributable to COPD were estimated at $32.1 billion dollars annually. In 2011, 12.7 million US adults were estimated to have COPD.

PR is a treatment program for people with COPD and is considered an essential component of care. MHS had previously developed the protocol to safely allow PR in the patient’s home, and will work with Novu to deliver the program, which focuses on daily movement and monitoring patient health. COPD patients who exercise at even very low levels significantly lower their risk of hospital admission and mortality. In the next phase, it will be tested in controlled human study at the Mayo Clinic to determine its effectiveness at improving quality of life and increasing daily steps.

 “COPD is a costly, debilitating disease for millions of Americans, and the delivery of effective treatment is ripe for innovation,” said Ali Shirvani-Mahdavi, Executive Vice President, Strategy and Programs, at Novu. “We believe that digital consumer tools can enable traditional protocols to work more efficiently in reaching patients, reducing hospital admissions and creating better outcomes. We are excited to partner with MHS and Mayo in this effort.”

Novu is a SaaS-based consumer engagement platform designed to align consumers and the health care ecosystem. The company connects data and technology with programs, challenges, community and rewards to create unique, personalized health experiences that target outcomes for the health care system. Leveraging advanced campaign management, gamification and data-driven consumer insight, Novu cultivates new relationships and loyalty to achieve better health across the care continuum. The company recently raised  $20M in funding from SSM Partners and Noro-Moseley Partners.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |